GlibenclamideHypoglycaemia following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1857卷 / 1期

关键词：

D O I：

10.1007/s40278-021-96547-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：162 / 162

相关论文

共 50 条

[21] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2020, 1802 (1) : 114 - 114
[22] CyproteroneMeningiomas following off-label use: case report
[J]. Reactions Weekly, 2021, 1849 (1) : 152 - 152
[23] DexamfetamineHypertension following off-label use: case report
[J]. Reactions Weekly, 2021, 1883 (1) : 150 - 150
[24] FavipiravirNephrotoxicity following off-label use: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 283 - 283
[25] RituximabPancytopenia following off-label use: case report
[J]. Reactions Weekly, 2020, 1807 (1) : 176 - 176
[26] DexamethasoneHyperglycaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1896 (1) : 173 - 173
[27] MirtazapineTachyphylaxis following off-label use: case report
[J]. Reactions Weekly, 2018, 1703 (1) : 182 - 182
[28] TocilizumabAnaphylaxis following off-label use: case report
[J]. Reactions Weekly, 2021, 1865 (1) : 397 - 397
[29] NivolumabFever following off-label use: case report
[J]. Reactions Weekly, 2016, 1601 (1) : 186 - 186
[30] CeftriaxoneCholelithiasis following off-label use: case report
[J]. Reactions Weekly, 2021, 1880 (1) : 118 - 118

← 1 2 3 4 5 →